The content on this site is intended for healthcare professionals only
Dr Saavedra speaks with ecancertv at the ecancer Colombian Cancer Congress about a novel anti-cancer vaccine, Cimavax.
She describes the immuno-targeting of the vaccine against EGF, and how blocking this pathway can halt cancer cell cycle progression.
Considering results from phase III studies, in treating advanced non-small cell lung cancer patients, Dr Saavedra reports a significant benefit for patients expression high levels of EGF.
WCLC 2025: Latest in EGFR positive NSCLC
Key insights from lung cancer research at ASCO 2025
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Choosing Wisely in radiology Tanzania
